Capreomycin sulfate

Name: Capreomycin sulfate
Brand: MedChemExpress
SKU: HY-17566
Rating: 5.0 (5 reviews)

Art. -Nr.: HY-17566 Reinheit: 99.0%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Capreomycin sulfate is a macrocyclic peptide antibiotic that inhibits phenylalanine synthesis in mycobacterial ribosomal translation. Capreomycin sulfate has anti-amyloidogenic and pro-fibrinolytic activities, reducing amyloid-induced cytotoxicity by inhibiting the occurrence of amyloid fibrillation. Capreomycin sulfate can be used in the study of multidrug-resistant tuberculosis, type 2 diabetes, Alzheimer's disease and Parkinson's disease.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Capreomycin sulfate Chemische Struktur

CAS. Nr. : 1405-37-4

Größe	Verfügbarkeit	Menge
500 mg	Auf Lager	Estimated Time of Arrival: December 31
1 g	Auf Lager	Estimated Time of Arrival: December 31
5 g	Auf Lager	Estimated Time of Arrival: December 31
10 g	Angebot einholen
50 g	Angebot einholen

or Massenanfrage

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

This product is a controlled substance and not for sale in your territory.

Kundenbewertung

Based on 5 publication(s) in Google Scholar

Other Forms of Capreomycin sulfate:

Capreomycin Angebot einholen

5 Publications Citing Use of MCE Capreomycin sulfate

Spezialitätsempfehlungen

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Alle Antibiotic Isoform-spezifische Produkte anzeigen:

Alle Isoformen anzeigen

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

Biologische Aktivität
Reinheit & Dokumentation
Verweise
Kundenbewertung

Beschreibung

IC₅₀ & Target

Aminoglycoside

In Vitro

Capreomycin sulfate (10-200 μM; 80 h) inhibits the formation of insulin fibrils in human erythrocytes in a concentration-dependent manner (IC₅₀=69.98 μM) and has a delayed fibrillation process^[3].
Capreomycin sulfate (75-100 μM; 60 min) shows a dose-dependent protective effect against amyloid fibril-induced erythrocyte damage and hemolysis^[3].
Capreomycin sulfate (100 μM; 0-48 h) effectively destroys fibrils in erythrocytes in a time-dependent manner^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[3]

Cell Line:	human erythrocyte
Concentration:	75 and 100 µM
Incubation Time:	30 min
Result:	The hemolysis rates were 23.8% and 13.0% at 75µM and 100µM, respectively.

In Vivo

Capreomycin sulfate (1.4-14.5 mg/kg for insufflation; 20 mg/kg for i.m., 4 weeks) decreases the wet lung weight and lowers bacterial burden in the lungs of infected guinea pigs^[2].

Pharmacokinetic Analysis in the guinea pig model^[2]

Route	Dose (mg/kg)	AUC_0-t (ng h/mL)	CL_F (mL/h kg)	K (h^-1)	t_1/2 (h)	MRT (h)	C_max (ng/mL)	T_max (h)	MAT (h)	F_0-t
i.v.	20	49.29	0.42	0.92	0.75	0.88	53.36	0.08	/	1.00
i.m.	20	58.2	0.35	0.68	1.09	1.44	32.33	0.36	0.44	1.20
Insufflation	14.5	16.95	0.54	0.48	1.53	1.80	6.70	0.31	0.80	0.54
Insufflation	7.2	8.2	0.52	0.45	1.68	1.72	3.34	0.38	0.72	0.59
Insufflation	1.4	1.15	0.67	0.71	1.22	1.01	0.92	0.5	/	0.41

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male guinea pigs [836 ± 162.3 g; infected via the respiratory route with nebulized suspensions 2 × 105 CFU/mL of Mycobacterium tuberculosis (strain H37Rv)] ^[2]
Dosage:	1.4, 7.2, and 14.5 mg/kg for Insufflation; 20 mg/kg for Intramuscular injection
Administration:	Insufflation or Intramuscular injection; 4 weeks
Result:	Decreased the wet lung weight at 14.5 mg/kg, and smaller than receiving 1.4 mg/kg group and controls. Lowered bacterial burden in the lungs (3.52 CFU/mL) at 14.5 mg/kg than controls (4.58 CFU/mL) and at 1.4 and 7.2 mg/kg (4.02 and 4.01 CFU/mL, respectively)

CAS. Nr.

1405-37-4

Appearance

Solid

Color

White to off-white

SMILES

OS(O)(=O)=O.[R]C[C@H](N1)C(N[C@@H](CNC(CC(N)CCCN)=O)C(N/C(C(N[C@H](C(NC[C@H](N)C1=O)=O)[C@@H]2NC(NCC2)=N)=O)=C\NC(N)=O)=O)=O.OS(O)(=O)=O.[R=OH 1A].[R=H 1B]

Structure Classification

Initial Source

Microorganisms

Streptomyces capreolus

Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

-20°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Lösungsmittel & Löslichkeit

In Vitro:

H₂O : 100 mg/mL (Need ultrasonic)

Molaritätsrechner
Verdünnungsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS
Solubility: 100 mg/mL; Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Reinheit & Dokumentation

Purity: 99.52%

Select Batch:

Data Sheet (282 KB) SDS (393 KB)

COA (252 KB) LCMS (96 KB)

Handling Instructions (2659 KB)

Verweise

[1]. Maus CE, et al. Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2005 Feb;49(2):571-7. [Content Brief]

[2]. Garcia-Contreras L, et al. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob Agents Chemother. 2007 Aug;51(8):2830-6. [Content Brief]

[3]. Siddiqi M K, et al. Capreomycin inhibits the initiation of amyloid fibrillation and suppresses amyloid induced cell toxicity[J]. Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics, 2018, 1866(4): 549-557. [Content Brief]

[4]. Reisfeld B, et al. A physiologically based pharmacokinetic model for capreomycin[J]. Antimicrobial agents and chemotherapy, 2012, 56(2): 926-934. [Content Brief]

[5]. Le Conte P, et al. Pharmacokinetics, toxicity, and efficacy of liposomal capreomycin in disseminated Mycobacterium avium beige mouse model[J]. Antimicrobial agents and chemotherapy, 1994, 38(12): 2695-2701. [Content Brief]